Clinical trials are becoming dramatically more complex. New therapies generate unprecedented volumes of data across labs, imaging systems, biomarkers, patient-reported outcomes, and operational tools. Yet the infrastructure used to run trials has barely evolved.

Clinical trials already generate enormous amounts of data across labs, imaging systems, CRO tools, and operational platforms. The real challenge is that none of these systems speak the same language, leaving clinical teams to manually stitch together fragments of the trial before they can answer even basic questions about safety, efficacy, or site performance.

This is the gap Rivia is addressing and the reason we chose to back the company.

The Hidden Bottleneck in Clinical Development

Clinical development is fundamentally a decision-making process. At every stage of a trial, teams must determine whether to escalate a dose, expand a cohort, intervene for safety reasons, or stop a program altogether.

Yet the systems supporting those decisions were never designed to provide a unified view of the trial.

Three structural issues have emerged as trials have grown more complex.

1. Data Lives Everywhere, But Nowhere Together

Modern clinical trials generate enormous amounts of data from many different sources: electronic data capture systems, imaging vendors, laboratories, biomarker platforms, patient-reported outcomes, and operational tools.

Each system holds only a fragment of the full picture. Clinical teams often spend days or weeks exporting datasets, reconciling formats, aligning patient identifiers, and rebuilding analyses just to answer basic questions about safety or efficacy.

As a result, even simple clinical questions can take days or weeks to answer, slowing dose decisions, safety reviews, and operational interventions that should happen in near real time.

2. Trial Complexity Is Outpacing Infrastructure

Trials today are more data-intensive and operationally complex than ever before. Protocols evolve, endpoints shift, and multiple vendors contribute data streams that rarely interoperate natively. Sponsors remain fully responsible for safety oversight and regulatory submissions, yet they lack a system that provides a real-time, integrated view of the entire study.

In practice, many teams rely on spreadsheets, static dashboards, or CRO-generated reports that arrive long after decision deadlines.

3. Operational Risks Surface Too Late

When clinical, operational, and safety data are siloed, signals emerge only after problems have already compounded. Recruitment delays, protocol deviations, inconsistent lab data, or safety patterns may remain invisible until a manual analysis surfaces them.

These blind spots introduce risk, increase trial costs, and slow the pace of innovation across the industry.

Rivia: A Unified Intelligence Layer for Clinical Trials

Rivia approaches this problem from a different angle.

Instead of replacing existing clinical systems, the platform sits above them, unifying data from across the trial ecosystem into a harmonized, protocol-aware data foundation. Once data is unified, Rivia deploys workflow-embedded AI agents that help clinical teams detect safety signals, identify emerging efficacy patterns, and surface operational risks earlier in the trial lifecycle.

In simple terms, Rivia turns fragmented datasets into a real-time operational view of the trial.

This allows:

— Medical teams to detect safety patterns earlier
— Clinical operations teams to identify site performance issues faster
— Data management teams to resolve inconsistencies sooner
— Biostatisticians to explore hypotheses without rebuilding datasets manually

Instead of waiting for CRO listings or stitched-together reports, teams can understand what is happening in the trial as it unfolds, spotting safety signals earlier, identifying operational risks sooner, and making critical study decisions with far better visibility.

Why the Team Stood Out

Clinical development is one of the most complex and regulated environments in enterprise software. Building infrastructure for this space requires deep domain credibility.

Rivia’s founders combine experience across clinical development, data science, and large-scale enterprise systems. Their backgrounds include work inside pharmaceutical organizations and clinical technology ecosystems, giving them a first-hand understanding of how trials actually operate.

What stood out to us was the team’s ability to translate clinical complexity into product design. Customers consistently describe Rivia not as another analytics tool, but as a system that understands the logic of how trials are run. That credibility has allowed the company to earn trust with both emerging biotech companies and larger pharmaceutical organizations early in its journey.

A Structural Opportunity in the Clinical Data Stack

The broader market context reinforces our conviction.

Clinical trials are among the most data-intensive workflows in healthcare, yet the technology stack remains highly fragmented. Most existing vendors focus on narrow functions, data capture, document management, analytics, or operational dashboards. What the industry lacks is a unifying intelligence layer capable of harmonizing data across all these systems.

This is the role Rivia is stepping into.

By anchoring itself in trial execution (where data is generated and decisions are made), the platform becomes the place where clinical, operational, and safety insights converge. From there, the opportunity expands across the broader clinical lifecycle, from trial design and feasibility, to regulatory readiness and portfolio-level analytics.

Looking Ahead

Clinical trials will only become more complex. New modalities, decentralized studies, and increasingly sophisticated biomarkers will continue to expand the amount of data generated during development. The organizations that succeed will be those that can turn that data into decisions faster.

We believe Rivia is building the infrastructure that enables this shift.

By transforming fragmented clinical datasets into a unified intelligence layer, the company has the potential to reshape how trials are monitored, analyzed, and ultimately executed.

We are proud to partner with Erik, Tiago, and the team as they build the next generation of clinical trial infrastructure. Delighted to lead their Series A with participation from new investor Defiant as well as existing investors at Speedinvest, Amino Collective, and Nina Capital.

Welcome to Earlybird, team Rivia!